Of stool samples of 552 subjects, 23.0% (127/552; [CI 19.5, 26.5]) were found RV positive. Rotavirus positivity was higher in the months of January (36.5% [19/52]), February (33.9% [19/56]), and March (38.7% [36/93]) (Fig. 2). Monthwise enrollment and rotavirus positivity for total PP population and region-wise is depicted in Fig. 2. RT-PCR was done for 85.8% (109/127) of RV positive samples (Fig. 3); for the rest of the samples, RT-PCR could not be done because

of inadequate stool quantity. Among these 109 samples, we identified G1, G2, G9, and G12 in 34.9% (38/109), Bioactive Compound Library purchase 37.6% (41/109), 8.3% (9/109), and 6.4% (7/109) stool samples, respectively. We identified P[4] and P[8] in 36.7% (40/109) stool samples each, followed by P[6] identified in 15.6% (17/109) stool samples. Most common GP types were G1P[8] and G2P[4] identified in 32.1% (35/109) and 27.5% (30/109) stool samples respectively. We found mixed infection of more than one G type in 6.4% (7/109) stool samples

which were all G1 + G2 type. Mixed P type infection was found in 4.6% (5/109) stool samples, which were P[4] + P[6], P[4] + P[8], and P[8] + P[6] in 1.8% (2/109), 1.8% (2/109), and 0.9% (1/109) stool samples respectively. There were also some untypeable strains (G untypeable: 6.4% [7/109], P untypeable: 6.4% [7/109], and both G and P untypeable: 4.6% [5/109]). Table 2 describes the presence and duration of AGE symptoms during the study period. At enrollment, we observed the co-occurrence of all three symptoms (vomiting, diarrhea, and fever) in higher proportion of RV positive subjects compared to RV negative subjects (60.6% CT99021 [77/127] vs. 42.8% [182/425], p = 0.0004). A higher proportion of RV negative subjects presented with only diarrhea (without vomiting and fever) compared to RV positive subjects Rolziracetam (22.8% [97/425] vs. 10.2% [13/127], p = 0.0018). The severity of RV positive and negative cases determined by Clark scale and Vesikari scale is presented in

Table 2. The proportion of subjects with higher AGE severity was statistically significant among RV positive subjects compared to RV negative subjects by both the scales (Vesikari scale: p = 0.0026, Clark scale: p = 0.0004). For RV positive subjects, the disease was mild, moderate, and severe for 4.7% (6/127), 18.1% (23/127), and 77.2% (98/127) subjects, respectively by the Vesikari scale. By the Clark scale, disease severity was mild, moderate, and severe for 26.8% (34/127), 69.3% (88/127), and 3.9% (5/127) subjects, respectively. The total direct cost including costs incurred prior to OPD visit, on the day of OPD visit, and from OPD till Day 14 were statistically higher (p <0.0001) for RV positive subjects (3177 INR) compared with RV negative subjects (1787 INR). The total direct cost incurred for most subjects, i.e., 97.6% (124/127) RV positive and 98.6% (419/425) RV negative subjects was 10,000 INR or less.